Feature Story

A global conference on the latest stem cell research

July 29, 2020

In June, the Harvard Stem Cell Institute (HSCI) co-sponsored the annual meeting of the International Society for Stem Cell Research. Held virtually for the first time, the conference brought together close to 4,000 scientists from 59 countries to discuss the latest in stem cell research.

David Scadden, co-director of HSCI, opened the conference by welcoming attendees and encouraging researchers to apply their expertise in stem cell science to the ongoing COVID-19 pandemic: “This has been a time of great crisis and upheaval that has really reminded us of the extraordinary power...

Read more about A global conference on the latest stem cell research

Highlights from the 2019 HSCI Annual Retreat

May 30, 2019

Boston-area stem cell scientists convene to discuss regulation, future research directions, career paths

The Harvard Stem Cell Institute (HSCI) convened for its 14th annual retreat on May 21st at Harvard Medical School in the Joseph B. Martin Conference Center. The event was a mix of presentations and panels, with poster sessions and topic tables in the New Research Building’s sunny atrium and courtyard.

Program Highlights

Around 300 HSCI scientists welcomed keynote speaker...

Read more about Highlights from the 2019 HSCI Annual Retreat

HSCI's 15th anniversary

April 26, 2019

The Harvard Stem Cell Institute (HSCI) was launched in 2004 with the express goal of pursuing the promise of stem cell science. In April 2019 we celebrate our 15th anniversary, and reflect on how far we have come.

Collaboration across Harvard

Our founding document listed 28 participating Harvard faculty, including co-founders Doug Melton and David Scadden. By May 2004 that list had expanded to 39 faculty, and in 2005 the number had almost doubled.

Since then, HSCI has grown to ...

Read more about HSCI's 15th anniversary

HSCI-supported research leads to new class of therapeutics

December 13, 2018

Biotech company Moderna, co-founded by HSCI scientist Derrick Rossi, is set to bring a new class of treatments to patients.

Summary

  • Derrick Rossi’s research into using mRNA as a new kind of therapeutic was initially supported by HSCI seed funding, and gave rise to biotech company Moderna Therapeutics.
  • Moderna’s public offering of $600 million is the largest ever of a venture-capital-backed biotechnology company, reflecting the potential of its new technology: mRNA therapeutics
  • Moderna’s success in creating therapies that will benefit patients reflects the crucial role of HSCI in enabling early-stage, high-risk research.

... Read more about HSCI-supported research leads to new class of therapeutics

Healing without scars

November 7, 2018

George Murphy wants to use stem cells to replace scarring with regenerative healing.

  • George Murphy’s goal is to coax skin stem cells into healing wounds by regenerating tissue instead of forming a scar.
  • To figure out how to do it, he is studying scarless healing during fetal development and “stem cell burnout” during aging.
  • Insights into scarless healing will help research into regenerating other vital organs, including the heart.

...

Read more about Healing without scars